Activity Date: 04/08/2024
Sign in (or create a FREE account) to access this FREE session!Currently approved drugs for schizophrenia have proven useful; however, unmet medical needs still exist for this patient population. This program will shed light on possible mechanisms for an innovative class of therapeutics that have shown promise in schizophrenia by targeting muscarinic acetylcholine receptors in the brain.
José Rey, MS, PharmD, BCPP
View biographical information and disclosuresAAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
The bookmark/discussion system is temporarily disabled. Please check back later.
Supported by Karuna, a Bristol Myers Squibb Company